Embryonic Stem Cell Marker Expression Pattern in Human Mesenchymal Stem Cells Derived from Bone Marrow, Adipose Tissue, Heart and Dermis

被引:0
作者
Una Riekstina
Inese Cakstina
Vadims Parfejevs
Martin Hoogduijn
Georgs Jankovskis
Indrikis Muiznieks
Ruta Muceniece
Janis Ancans
机构
[1] University of Latvia,Faculty of Medicine
[2] University of Latvia,Faculty of Biology
[3] University of Latvia,Institute of Experimental and Clinical Medicine
[4] Erasmus Medical Center,Department of Internal Medicine, Transplantation Laboratory
来源
Stem Cell Reviews and Reports | 2009年 / 5卷
关键词
Human mesenchymal stem cells; Oct4; Nanog; SOX2; SSEA-4;
D O I
暂无
中图分类号
学科分类号
摘要
Mesenchymal stem cells (MSCs) have been isolated from a variety of human tissues, e.g., bone marrow, adipose tissue, dermis, hair follicles, heart, liver, spleen, dental pulp. Due to their immunomodulatory and regenerative potential MSCs have shown promising results in preclinical and clinical studies for a variety of conditions, such as graft versus host disease (GvHD), Crohn’s disease, osteogenesis imperfecta, cartilage damage and myocardial infarction. MSC cultures are composed of heterogeneous cell populations. Complications in defining MSC arise from the fact that different laboratories have employed different tissue sources, extraction, and cultivation methods. Although cell-surface antigens of MSCs have been extensively explored, there is no conclusive evidence that unique stem cells markers are associated with these adult cells. Therefore the aim of this study was to examine expression of embryonic stem cell markers Oct4, Nanog, SOX2, alkaline phosphatase and SSEA-4 in adult mesenchymal stem cell populations derived from bone marrow, adipose tissue, dermis and heart. Furthermore, we tested whether human mesenchymal stem cells preserve tissue-specific differences under in vitro culture conditions. We found that bone marrow MSCs express embryonic stem cell markers Oct4, Nanog, alkaline phosphatase and SSEA-4, adipose tissue and dermis MSCs express Oct4, Nanog, SOX2, alkaline phosphatase and SSEA-4, whereas heart MSCs express Oct4, Nanog, SOX2 and SSEA-4. Our results also indicate that human adult mesenchymal stem cells preserve tissue-specific differences under in vitro culture conditions during early passages, as shown by distinct germ layer and embryonic stem cell marker expression patterns. Studies are now needed to determine the functional role of embryonic stem cell markers Oct4, Nanog and SOX2 in adult human MSCs.
引用
收藏
页码:378 / 386
页数:8
相关论文
共 109 条
[1]  
Friedenstein AJ(1966)Osteogenesis in transplants of bone marrow cells Journal of Embryology & Experimental Morphology 16 381-390
[2]  
Piatetzky-Shapiro II(2009)Genomic profiling of mesenchymal stem cells Stem Cell Reviews and Reports 5 36-50
[3]  
Petrakova KV(2001)Human reserve pluripotent mesenchymal stem cells are present in the connective tissues of skeletal muscle and dermis derived from fetal, adult, and geriatric donors Anatomical Record 264 51-62
[4]  
Menicanin D(2007)Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair—current views Stem Cells 25 2896-2902
[5]  
Bartold PM(2007)Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities Stem Cells and Development 16 597-604
[6]  
Zannettino AC(2006)Isolation and characterization of a population of immature dental pulp stem cells expressing OCT-4 and other embryonic stem cell markers Cells Tissues Organs 184 105-116
[7]  
Gronthos S(2007)Multipotent cells can be generated in vitro from several adult human organs (heart, liver, and bone marrow) Blood 110 3438-3446
[8]  
Young HE(2002)Human adipose tissue is a source of multipotent stem cells Molecular Biology of the Cell 13 4279-4295
[9]  
Steele TA(2007)From the laboratory bench to the patient’s bedside: an update on clinical trials with mesenchymal stem cells Journal of Cellular Physiology 211 27-35
[10]  
Bray RA(2007)Mesenchymal stem cell tissue engineering: techniques for isolation, expansion and application Injury 38 S23-S33